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                                          INTRODUCTION
It was in the year 1960, Nowell and Hungerford discovered the “minute chromosome”.1 More 
than a decade later, Janet rowely’2 described the presence of t(9;22).  This has lead to the 
evolution in treatment of CML from “carpet bombing” to the modern day targeted therapy, the  
“magic bullet” – Imatinib Mesylate.  
In June 1998, the drug was given to the first human volunteer with CML in the phase I trial 3 4. 
Patients were either unresponsive to interferon (IFN), or in advanced phase.  In the next three 
phase II trials, the efficacy of this drug in all the phases of CML were confirmed.5 6,7.  However, 
it was the landmark phase III trials that established its present status as the first line drug of  
choice in the management of newly diagnosed cases of CML.  This multicentre prospective 
trial proved its true virtue with clear superiority in cytogenetic response rates as compared 
with the “gold standard” of that time; INF administered along with low dose cytosine. 8,9
Marketed by the Novartis, Switzerland (Gleevec or Glivec) at a prize of approximately Rs 
100,000 per month, it was affordable only by the patient of developed countries.  In the United 
States, initially it was approved only for patients with INF unresponsive CML in chronic phase 
(CP) and in advanced phase.  Subsequently, in December 2002, its use in newly diagnosed 
CML in  CP  was  approved  by  US-FDA (Food  and  Drug  Administration).   Many  Indian 
companies launched Imatinib through reverse engineering (Since January 2003) before the 
exclusive marketing rights (EMR) were granted to Novartis. Although it was sold at a fraction  
of cost of Glivec, it was unaffordable to the majority of patients. 
CML patients from 60 odd nations benefited when Max foundation (started in memory of 
Maxmillano from Argentina who died of CML at the age of 17 yrs) supported the developing 
countries with its generous GIPAP (Glivec International  Patient Assistance Program). This 
program was initially restricted to patients resistant to INF unresponsive CML-CP or advanced 
phase disease and subsequently from April 2003, it was opened for first line therapy for CML.  
With the introduction of this efficient and well run program it is possible for practically every  
newly diagnosed patient with CML in India to be enrolled and treated with this drug.   With the  
cost of the drug being absorbed by the GIPAP, it has become the choice of front line therapy 
because of the reduced cost  of  treatment and proven benefit  in this condition. The latter 
however was based on extrapolation from data generated from the West and it is potentially  
possible that there could be differences in both the efficacy and toxicity profile of this drug 
among Indian patients.
This study aims to look into the profile of CML patients in coming to CMC Vellore who are on 
Imatinib.
                                         REVIEW OF LITERATURE
Chronic myeloid leukemia (myelogenous, myelocytic, granulocytic) leukemia (CML) is a clonal 
myeloproliferative disorder of a pluripotent hematopoietic stem cell with a specific cytogenetic  
abnormality, the Philadelphia (Ph+) chromosome. This chromosome results from a balanced 
translocation  between the  long  arms of  chromosomes 9  and  22,  resulting  in  the  bcr/abl  
chimeric gene that expresses an abnormal fusion protein with altered tyrosine kinase activity.  
CML accounts for 7% to 20% of all leukemia and affects an estimated 1 to 2/100,000 persons 
in the general population.10  The clinical presentation often includes granulocytosis, marrow 
hypercellularity  and  splenomegaly.   The  natural  course  of  the  disease  involves  three 
sequential  phases (Chronic,  accelerated, and blast crisis).   Chronic phase can persist for 
years, but the accelerated phase and blast crises last only for months. Each phase of the 
disease becomes more resistant to therapy.11
History of CML and pathogenesis: 
             The first description of cases of CML was made by two pathologists, Dr Robert Virchow and 
Dr John Hughes Bennett in 1845.12,13 Although a debate ensued as to whose description  was 
first, Virchow publicly acknowledged that Bennett’s  case report had predated his.14 These first 
accounts of CML occurred before staining methods for blood, which were not developed  until 
the late 1800s. 
      After  115 years of  the initial  description of the disease, Philadelphia chromosome was  
described in the seminal paper by Nowell and Hungerford.1 What ensued was a long history 
of scientific discoveries that led to an unraveling of the molecular pathogenesis of CML.  In 
1973,  Dr  Janet  Rowley  determined  that  the  shortened  chromosome  22,  the  so-called 
Philadelphia chromosome, was the product of  a reciprocal translocation between the long 
arms of chromosomes 9 and 22, t(9:22)(q34;q11).2 In 1982, by mapping oncogenes to specific 
chromosomal  locations,  it  was recognized that  the c-ABL tyrosine kinase,  which  normally 
resides  on  chromosome 9,  had  been  translocated  to  chromosome 22  in  CML patients.15 
Shortly thereafter,  Eli  Canaani  et  al  showed that  a  chimeric mRNA called  BCR-ABL was 
present in patients with CML that was larger than the normal c-ABL mRNA.16  One year later, 
Owen Witte and David Baltimore demonstrated that a chimeric, BCR-ABL protein  was made 
and that it possessed tyrosine kinase activity.17It was in 1990 that BCR-ABL could be put into 
animal  models  to  demonstrate  that  BCR-ABL,  as  the  sole  oncogenic event  that  induced 
leukemia, thus establishing BCR-ABL as a leukemic oncogene.18,19
Cytokinetics
CML  develops  when  a  single,  pluripotential,  haematopoietic  stem  cell  acquires  a  Ph 
chromosome carrying the BCR-ABL fusion gene, which confers on its progeny a proliferative 
advantage  over  normal  haematopoietic  elements  and  thus  allows  the  Ph-positive  clone 
gradually  to  displace  residual  haematopoiesis.20 The  proliferative  advantage  has  been 
postulated to either to constitutive expression by leukemic progenitors of growth factors (G 
CSF)21, interleukin-322, mitogenic signalling23 or a defective apoptotic response to stimuli that 
would have lead to physiologic cell death.24 The other mechanism implicated in the malignant 
transformation  by  Bcr-Abl  is  the  altered  adhesion  to  stroma  cells  and  extra  cellular 
matrix.25CML cells  express  adhesion  inhibitory variant  of  β1  integrin  that  is  not  found  in 
normal progenitors.26
Molecular biology of CML27:
ABL
The ABL gene is the human homologue of the v-abl oncogene carried by the Abelson murine 
leukemia virus (A-MuLV), and it encodes a nonreceptor tyrosine kinase.  ABL gene has 11 
exons and spans over 230 kilobases.  The breakpoint in the  ABL  gene occurs usually 5' 
(toward the centromere) of exon 2 of ABL. The ABL exons 2 to 11 (also called a2 to a11) are 
transposed into the major breakpoint cluster region (M-bcr) of the BCR gene on chromosome 
22 between exons 12 and 16 (also referred to as b1 to b5), which extends over 5.8 kb.
Human Abl is a ubiquitously expressed 145-kd protein with 2 isoforms arising from alternative 
splicing of the first exon. Several structural domains can be defined within the protein (Figure 
1). Three SRC homology domains (SH1-SH3) are located toward the NH2 terminus. The SH1 
domain carries the tyrosine kinase function, whereas the SH2 and SH3 domains allow for 
interaction with other proteins. Proline-rich sequences in the center of the molecule can, in 
turn, interact with SH3 domains of other proteins, such as Crk.13 Toward the 3’ end, nuclear 
localization signals and the DNA-binding and actin-binding motifs are found. 
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Functionally, Abl protein serves a complex role as a cellular module that integrates signals 
from  various  extracellular  and  intracellular  sources  and  that  influences  cell  cycle  and 
apoptosis. Knock out mice showed neonatal lethality and lymphopenia with a homozygous 
disruption of the c-abl proto-oncogene in one study28 and viability with depletion of selected B 
and T cell populations in another study.29 The ABL protein is found in both the nucleus and the 
cytoplasm  and  can  shuttle  between  these  two  compartments  under  the  influence  of  its  
nuclear-export signal domain, whereas BCR-ABL is exclusively cytoplasmic.  Nuclear ABL is 
an essentially proapoptotic protein, playing a key part in the cellular response to gentoxic 
stress. 30
BCR27
The Bcr is a 160-kd protein, like Abl, which is also ubiquitously expressed (23 exons).  It has 
an N terminal exon which encodes a serine–threonine kinase. A coiled–coil domain at the N-
terminus of Bcr allows dimer formation in vivo. The center of the molecule contains a region 
with dbl-like and pleckstrin-homology (PH) domains.  Bcr can be phosphorylated on several  
tyrosine residues, especially tyrosine 177, which binds Grb-2, an important adapter molecule  
involved in the activation of the Ras pathway. However,  BCR knockout mice are viable and 
the only recognized defect is increased oxidative burst in neutrophils.31
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Figure 2: DD – Dimerization Domain or the coiled coil domain at the N terminus of Bcr which 
allows dimmer formation in vivo. Tyrosine 177 (Y-177) in the BCR portion of the fusion gene is 
important of the docking of adapter proteins like Grb-2 which has a role in RAS pathway. RHO 
GEF: GTP-GDP exchange factor which may activate transcription factors such as NF-kB.
BCR-ABL
The breakpoints within the ABL gene at 9q34 can occur anywhere over a large (greater than 
300 kb) area at its end, upstream of exon 2 (Figure 3) and simultaneously a break occurs in 
the major  breakpoint cluster region of the BCR gene. As a result, a 5’ portion of BCR and a 3’ 
region of ABL are juxtaposed on a shortened chromosome 22 (the derivative 22q-, or Ph 
chromosome).  Regardless of  the exact  location of  the breakpoint,  splicing of  the primary 
hybrid transcript yields an mRNA molecule in which BCR sequences are fused to ABL exon 
a2. In contrast to  ABL, breakpoints within  BCR localize to 1 of 3 breakpoint cluster regions 
(bcr). In most patients with CML and in approximately one third of patients with Ph-positive  
acute lymphoblastic leukemia (ALL), the break occurs within a 5.8-kb area spanning  BCR 
exons 12-16 (originally referred to as exons b1-b5), defined as the major breakpoint cluster 
region (M-bcr).  A  BCR–ABL  fusion gene with a b2a2 (e13a2) or b3a2 (e14a2) junction is 
created and transcribed into an 8.5-kb mRNA. The fusion mRNA is translated into a chimeric 
protein of 210 kd called p210BCR–ABL.
In the remaining patients with ALL and rarely in patients with CML, the breakpoints are further  
upstream in the 54.4-kb region between the alternative  BCR  exons e2.  (minor breakpoint 
cluster region (m-bcr). The resultant e1a2 mRNA is translated into a 190-kd protein (P190BCR-
ABL). Recently, a third breakpoint cluster region (m-bcr) was identified downstream of exon 19, 
giving rise to a 230-kd fusion protein (P230BCR-ABL) associated with the rare Ph-positive chronic 
neutrophilic leukemia, though not in all cases. 
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ABL exon 1, even though retained in the genomic fusion, is never part of the chimeric mRNA. 
Thus,  it  must  be  spliced  out  during  processing  of  the  primary  mRNA;  the  mechanism 
underlying this apparent peculiarity is unknown. Based on the observation that the Abl part in  
the chimeric protein is almost invariably constant while the Bcr portion varies greatly, one may 
deduce that Abl is likely to carry the transforming principle whereas the different sizes of the 
Bcr sequence may dictate the phenotype of the disease.27
The leukemogenic  potential  of  p210BCR-ABL resides in  the  fact  that  the  normally  regulated 
tyrosine kinase activity of the ABL protein is constitutively activated by the juxtaposition of 
BCR sequences. BCR acts by promoting dimerization of the oncoprotein, such that the two 
adjacent BCR-ABL molecules phosphorylates each other on tyrosine residues in their kinase-
activation loops.32  The uncontrolled kinase activity of BCR-ABL then up regulates the normal 
physiological functions of the normal ABL enzyme by interacting with a variety of  effector  
proteins resulting in deregulated cellular proliferation, decreased adherence of leukemia cells 
to the bone marrow stroma and reduced apoptotic response to mutagenic stimuli.33
The tyrosine kinase encoded by the SRC- homology 1 (SH1) domain of the ABL component 
of BCR-ABL is most crucial for oncogenic transformation.  SH3 domain on the ABL plays a  
critical role in regulating its tyrosine kinase activity. Fusion of the Bcr sequences to the 5’ end  
of Abl SH3 domain abrogates the physiologic suppression of the kinase. The other important 
motifs  in  the  ABL  portion  are  the  SH2  and  C  terminal  actin  binding  domains.  On 
autophosphorylation of the protein, SH2 creates binding sites for other adaptor proteins like  
Crkl  and  other  proteins  associated  with  organization  of  the  cytoskeleton  and  the  cell  
membrane.  Under  physiologic  conditions,  phosphatases  regulate  the  effects  of  tyrosine 
kinases; however, its significance in the transformation process is unknown.  On the BCR, the 
coiled-coil motif is responsible for the dimerization of the oncoprotein.  A tyrosine at postion 
177 (Y177)  is  crucial  for  binding of  adaptor  protein  Grb 2 (Growth  factor  receptor-bound 
protein  2).  The  N  terminal  phosphoserine  and  phosphothreonine  (P-S/T)  residues  are 
required for interaction with SH2 containing proteins including ABL.  Numerous substrates 
bind  to  BCR-ABL and  are  tyrosine  phosphorylated  by it  resulting  in  increased  mitogenic 
activity (via Ras, Myc, STAT, PI3K etc) decreased apoptosis (Bcr-Abl may block the release of 
cytochrome C from the mitochondria and decreased caspases and phosphorylation of pro-
apoptotic  protein  Bad.)  and  altered  adhesion  (CML cells  express  an  adhesion  inhibitory 
variant of β  integrin).27,33
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This phosphorylation of the effector protein requires binding of ATP to transfer the phosphate 
group. So any agent which could block the binding of ATP would prevent this transfer of 
phosphate  and  prevent  conformational  change  of  the  substrate  protein.  This  leads  to 
interruption of downstream pathway and interferes with oncogenic signal to the nucleus.
History of treatment of CML:
Fowler’s  solution (1% solution of Arsenic trioxide) was the mainstay of therapy for all ailments 
since 1786 and it  was being used for the treatment of CML during the late 1800s till  the  
introduction  of  radiation  therapy in  1903.34 With  its  introduction,  median  survival  of  CML 
patients increased to approximately 2 ½ years.  
An alkylating agent Busulfan was introduced in the 1950s with specific granulocyte series 
suppression.  35  This drug improved the median survival  to 3 ½ - 4 years.  In the 1960s, 
Hydroxyurea (Hydrea) was introduced. Being less toxic than Busulfan and non toxic to stem 
cells, this became popular. Randomized studies showed prolonged survival over busulfan. In  
the 60s and in the 80’s the median survival prolonged to four and a half years. Both Busulfan 
and Hydroxyurea remained the mainstay of treatment for the next 35 years.  However the 
onset of blast crisis was not delayed and myeloblastic transformation was typically resistant to 
chemotherapy.   Lymphoblastic  crises  could  be  achieved  remission  with  steroids  and 
vincristine.
Interferon was introduced for the treatment of CML in the 1980s. Although side effects were 
more, the median survival improved to 7 ½ years with interferon and induction of Ph negativity 
seemed to correlate with a low rate of blastic transformation.36 Meta-analysis showed that the 
pooled 5-year survival rate was 57% for recombinant interferon alpha (rIFN-a) and 42% for 
chemotherapy (Hydroxyurea and Busulfan) (P , .0001), which results from a delay in the onset 
of blast crisis.37,38Compared with BUS or HU, the controlled trials suggested that, on average, 
rIFN-a increased life expectancy by a median of about 20 months. Patients overall have a 
50%  to  59%  probability  of  being  alive  5  years  after  treatment,  which  represents  an 
improvement over the 29% to 44% 5-year survival rate seen with chemotherapy.39 The French 
multicentre randomized control trial  in 1997 showed further improvement in response with 
addition of cytosine along with interferon.40The combined therapy group had a significantly 
higher incidence of complete hematologic and cytogenetic remissions (66%  v  55%, 15%  v 
9%, respectively). The reported 3-year survival rate was 86% in the comibined group and 
79% for IFN alone.  This improvement of survival was correlated with the achievement of  
major cytogenetic remission.40,41 
Allogeneic bone marrow transplantation as a curative therapy for CML was introduced in 
1986. 42Survival rates after sibling donation were at first rather disappointing, but the outlook 
gradually  improved  as  the  importance  of  the  ‘antileukemic’  effect  of  T  cell  activity  was 
appreciated.43 Allogeneic stem cell transplant is an option in only 40% of CML patients. Long 
term survival rates Human leucocyte antigen (HLA) matched related bone marrow transplant 
range from 50% to 75% in patients with chronic phase CML. The major factors influencing 
survival are patient age, disease phase at the time of  stem cell transplant (SCT), disease 
duration, degree of histocompatibility between donor and recipient  and gender of  donor.44 
Survival rates after transplantation in accelerated phase approximately 50% lower, and 5 year  
survival rates are <20% for patients who receive transplants during blast crisis. 45,46 The risk of 
relapse after allogeneic transplant in CML is about 20%. Many patients who relapse respond 
to  donor  leukocyte  infusions  (adoptive  immunotherapy).47 However,  transplant  related 
mortality in CML ranges between 20 – 41% and incidence of grade II-IV acute GVHD between 
8% - 63% which is a possible deterrent to survival. The rates for chronic GVHD are 4% to 
75%, with 8% to 10% mortality in the next 10 – 20 years.39 The initial  studies showed a 
survival  advantage with  BMT over  IFN.  However,  both  groups were  not  comparable with 
better  prognostic  markers  in  the  BMT  group.  Gale  et  al48 attempted  to  control  for  the 
differences by comparing the survival of 548 patients from the International Bone Marrow 
Transplant Registry with 196 patients who had received rIFN-a or HU in the German RCT.49 
Survival  curves were  adjusted for  different  patient  characteristics  and duration  of  illness, 
showing that the percentage of patients surviving was less for BMT patients during the first 18 
months of treatment (reflecting early transplant-related mortality), similar between the groups 
from 18 to 56 months, but significantly better for BMT after 56 months (P , .0001). The 7-year 
probability of survival (and 95% confidence interval) was 58% (50% to 65%) for BMT and  
32% (22% to 41%) for  rIFN-a/HU,  with  the  survival  advantage first  becoming statistically 
significant after 5.5 years. The corresponding rates for patients transplanted within 1 year of 
diagnosis compared to those treated with rIFN-a/HU were 67% (56% to 75%) and 30% (21% 
to 40%), respectively, with the survival advantage appearing earlier at 4.8 years. These data 
supported the view that BMT produced better long-term outcomes, but concerns remained 
regarding the definitive evidence.  Till  the year  2003,  based on the above findings it  was 
recommended  that  BMT should  preferably  be  offered  to  patients  within  1  to  2  years  of  
diagnosis  to  achieve the greatest  likelihood of  success.  Patients  with  adverse prognostic 
factors (reflected by a high Sokal score) were offered upfront BMT over rIFN-a. For patients 
who have had CML for more than 1 year and for those who are considering delaying BMT 
until  more than 1 year from diagnosis, a decision was required of whether the decreased 
likelihood of benefit justified the risk of transplant. Young patients with CML were advised to 
undergo BMT if there was a matched related donor.39
Era of Imatinib
 Imatinib  which  was  earlier  called  as  STI-571  (Signal  transduction  inhibitor)  is  a  2- 
phenlyaminopyridine, is a prototype for signal transduction inhibitors.  It is a highly selective 
inhibitor of the protein kinase family which includes BCR-ABL protein, Platelet derived growth 
factor receptor (PDGFR) and the c-kit  receptor.50 Imatinib competitively binds to the ATP-
binding  site  of  BCR-ABL  and  inhibits  protein  tyrosine  phosphorylation.51 Initially  this 
compound was proven to inhibit BCR-ABL induced tumor formation in vitro in immunodeficient 
mice. In 1996, Druker et al confirmed that STI-571 (present Imatinib) prevented growth of 
haematopoietic cells that expressed BCR –ABL but did not affect normal cell function.52
Pre clinical studies: 
From  late  1980s,  scientists  at  Ciba  Geigy  (Now  Novartis)  had  initiated  projects  on 
identification of compounds with inhibitory activity against protein kinases. One such lead 
compound  was  2-phenylaminopyrimidine.  In  1992  53,  Anafi  and  colleagues  reported  a 
tyrphostin,  related to  erbstatin,  that  inhibited the tyrosine kinase activity of  BCR-ABL and 
suggested that it might be possible to design specific compounds for the treatment of ABL-
associated human leukemias.
By making a series of modification to the lead compound 2 – phenylaminopyrimidine, it was 
able  to  create  a  drug  which  specifically  bound  to  BCR-ABL.  Later  its  solubility  and  oral  
bioavailability  was  increased  by  adding  a  highly  polar  side  chain.  STI571  (formerly 
CGP57148B,  now  Imatinib  mesylate;  Gleevec  or  Glivec,  Novartis,  Basel,  Switzerland) 
emerged as the most promising compound for clinical development, since it had the highest 
selectivity for growth inhibition of BCR-ABL–expressing cells.
Studies  using  purified  enzymes expressed as  bacterial  fusion  proteins  or  using  immuno-
precipitations of intact proteins showed that Imatinib potently inhibits all of the ABL tyrosine  
kinases including cellular ABL(c-ABL), viral ABL (v-ABL), and BCR-ABL.54  The results of the 
kinase assays were confirmed in cell lines expressing constitutively active forms of ABL such 
as v-ABL, p210BCR-ABL, p185 BCR-ABL and translocated leukemia (TEL)–ABL, where Imatinib was 
found to inhibit ABL kinase activity with 50% inhibitory concentration (IC50) values ranging 
between 0.1 and 0.35µM. 55,56
In vivo profile of Imatinib: animal models
Once daily intraperitoneal injection of  Imatinib (2.5 – 50mg/Kg) in BCR-ABL transformed cell 
lines in syngeneic mice showed a dose-dependent inhibition of tumor growth.52,57.  Imatinib 
was also tested in the transduction-transplantation model  of  CML. In this system, lethally 
irradiated  syngeneic  mice  receive  marrow  infected  with  a  BCR-ABL  retrovirus  and 
consistently die within 3 weeks from an aggressive CML58. Treatment with Imatinib (50 mg/kg 
in the morning, 100 mg/kg in the evening) led to prolonged survival59.
Phase I clinical studies
Phase I  trials  with  Imatinib  began in  June of  1998 and were  designed to  determine the 
maximally tolerated dose, with clinical benefit as a secondary endpoint. Patients in the chronic 
phase of CML who had failed therapy with IFN were eligible3. Imatinib, given as daily oral 
therapy, was well tolerated, without dose limiting toxicity. Hematological responses were seen 
at doses of 140 mg and greater. Most remarkable was that 53/54 patients treated with at least  
300 mg showed complete hematologic responses (CHR). Moreover, at doses of 300 mg and 
higher,  cytogenetic responses were achieved in 31% of patients,  which were complete in 
13%. Pharmacokinetic studies revealed that above 300 mg, plasma levels equivalent to the 
effective in vitro level (1μM) were achieved. At 400mg, the current standard dose for CML in 
chronic phase, peak levels at  steady state were approximately 4.6 μΜ and trough levels 
approximately 2.13 μΜ, with a half-life of 19.3 hours, indicating that once-daily dosing was 
sufficient to provide continuous kinase inhibition60.
Phase I study was further expanded to patients with myeloid and lymphoid blast crisis of CML 
and patients with relapsed or refractory Ph-positive ALL4. With doses of 300 to 1000 mg/d, 
11% of patients with myeloid blast crisis achieved CHR, and another 10% a reduction of bone 
marrow blasts to <5%, without complete recovery of peripheral blood counts. In patients with 
lymphoid  disease,  the  corresponding  remission  rates  were  20%  and  15%,  respectively. 
Unfortunately, most patients with myeloid and all but one patient with lymphoid blasts crisis 
relapsed within weeks to months.
Phase II clinical studies
There were three phase 2 studies which began in the late 1999 using Imatinib as single agent  
in all  phases of CML. Patients in chronic phase who had failed IFN did much better than 
expected,  with  rates  of  CCR of  41% and  major  cytogenetic  remission  (MCR)  of  60% 5,7. 
Importantly, these responses were usually durable, resulting in a progression-free survival of 
89.2%  at  18  months.  The  efficacy  in  patients  with  accelerated  phase  was  intermediate 
between  chronic  phase  and  blast  crisis6.  And  Imatinib  in  blast  crises  showed  similar 
responses as in phase 1 study7. The results of the phase I and II trials led to the approval by 
the Food and Drug Administration of Imatinib for the treatment of CML in advanced phase and 
after failure of IFN
Phase 2 studies 61
Overall
hematologic
response/
CHR
(%)
Sustained
hematologic
responses
(> 4 weeks)
(%)
MCR
(%)
CCR
(%)
Median
survival
(%)
Myeloid 
blast  crisis 
(n = 229)
52/15 31 16 7 6.8  months
Ph-positive 
ALL* (%)
(n = 56)
52/22 27 NA NA 4.9 months
Accelerated 
phase 
(n = 181)
82/53 69 24 17 Not reached
Chronic 
phase after 
failure
of IFN
95% 
sustained 
CR
95% 
sustained 
CR
60 41 Not reached
*Also lymphoid blast crisis of CML. CHR – complete hematologic response; MCR – major  
cytogenetic response; CCR – complete cytogenetic response
Phase III clinical studies
Imatinib and the combination of IFN plus cytarabine were compared in a randomized trial,  
(IRIS - The International Randomized Study of Interferon and STI571) which showed Imatinib 
to  be  vastly  superior  with  respect  to  CHR,  MCR and  CCR as  well  as  progression  free 
survival8,62.
Responses to Imatinib vs.  IFN plus cytarabine in newly diagnosed CML patients in 
chronic phase8
CHR MCR CCR PFS  14 
months
Imatinib (%)
(n = 553)
95.3 85.2 73.8 92.1
IFN+ 
Cytarabine 
(%)
(n = 553)
 
55.5 22.1 8.5 73.5
p = .0001 0.001 0.001 .001
A recent update of the same group of patients with a  median follow-up of 54-months showed 
that, 72% of the 553 randomized pts remain on initial IM treatment (5% of pts discontinued 
due to adverse events, 9.5% due to unsatisfactory therapeutic effect and 11% due to other 
reasons another 2.5% crossed over to IFN+Ara-C). Overall,  the cumulative best response 
rates of CHR, MCyR and CCyR are 97%, 88% and 82%, respectively. The overall estimated 
survival was 90% (93% when censored at bone marrow transplant). An estimated 84% of pts 
have not progressed on treatment and 93% of pts were free from progression to AP/BC. The 
annual rate of progression to AP/BC of < 1% in the fourth year was lower than each of the first  
three years (1.5, 2.8, and 1.6%, respectively). Of the pts with MCyR at 12 months (n=436), an  
estimated 96% were free of progression to AP/BC at 54 months whereas it was only 81% for 
the 73 pts who did not achieve a MCyR at 12 months (p< 0.001). No patient with a MMR 
within 12 months progressed to AP/BC within 54 months.63
Adverse effects of Imatinib
Haematological toxicity
In the phase III  trial  with Imatinib therapy in newly diagnosed CML patients,  Neutropenia, 
thrombocytopenia and anemia of all grades occurred in 60.8%, 56.6% and 44.6% patients 
respectively. However, grades 3 and 4 toxicities in 25%, 16.5% and 4.3% respectively.62
It  is  unclear  why some patients  develop myelosuppression during  therapy.  Along with  its 
potent  inhibitory  effect  on  Bcr/Abl,  Imatinib  also  inhibits  c-kit,  which  is  involved  in  early 
hematopoiesis.52 Thus,  myelosuppression  may be  the  result  of  undesired  suppression  of 
normal  progenitors.64  Some reports  suggest  that  Imatinib  may impair  the colony forming 
capacity  of  CD34  positive  cells.65 However,  concentrations  of  Imatinib  similar  to  those 
achieved in vivo have very minimal effect on colony formation of normal progenitor cells in 
vitro.52 Furthermore, in patients without hematologic diseases (e.g., gastrointestinal stromal 
tumors) who are treated with Imatinib, hematological toxicity is far less common (5% develop 
neutropenia >/=Grade 3); it is manifested almost
exclusively by neutropenia and is seen mostly at higher doses.64
Non haematological toxicity
The most common side effects noted in the phase III trial were superficial edema, nausea, 
muscle cramps, and rashes. There were only rare occurrences of grade 3 or 4 events.
Table 4 Non Haematological toxicity profile in the IRIS study.8
Non  Haematological 
toxicity
All grades % Grade 3 or 4 %
Superficial oedema 55.5  0.9
Nausea 43.7 0.7
Muscle cramps 38.5 1.3
Musculoskeletal pain 36.5 2.7
Rash 33.9 2.0
Fatigue 34.5 1.1
Diarrhoea 32.8 1.8
Head ache 31.2 0.4
Joint pain 28.3 2.4
Myalgia 21.4 1.5
Dyspepsia 16.2 0
Weight gain 13.4 0.9
Cutaneous reactions to imatinib are common and occur in 9.5% to 69% of patients depending 
on the series reported.66 Hypopigmentation was not documented in the initial phases of trial. 
However, subsequently the same was noted especially in the dark skinned patients. Many 
case  reports  are  available  especially  in  the  African-American67 and  an  Indian  study  has 
mentioned 65% incidence of generalized hypopigmentation in the patients treated.68  Many 
patients  noticed  pigmentation  changes  within  one  month  of  initiation  of  treatment  and 
persisted throughout the course of therapy.  
Several lines of evidence have previously reported that KIT and its ligand stem cell factor  
(SCF) play a regulatory role in melanocyte development and survival, suggesting a rational 
mechanism of action for Imatinib Mesylate in the pathogenesis of hypopigmentation.69  This is 
supported by the observation that human mutations in the encoded tyrosine kinase region of  
KIT have been shown to cause piebaldism, an autosomal dominant disorder characterized by 
white hair and hypopigmented skin patches on the forehead, torso, and extremities.70
Of late, Imatinib has been shown to induce cardiac toxicity in the form of congestive cardiac 
failure secondary to mitochondrial injury.71
Pregnancy and Imatinib
The information on the potential effect of Imatinib on developing infant is limited. However, 
many  young  patients  frequently  face  the  dilemma  of  conception  and  pregnancy  while 
receiving Imatinib.  Patriticia et al  reported for the first  time a series of patients with such 
experience. Nineteen pregnancies involving 18 patients (10 females and eight males) who 
conceived while receiving Imatinib for the treatment of  CML were followed up.  All  female 
patients discontinued therapy immediately on recognition of pregnancy. Three pregnancies 
(involving two female patients and one male patient) ended in spontaneous abortion, and one 
patient had an elective abortion. All other pregnancies were uneventful. Two of the 16 babies 
had minor abnormalities at or shortly after birth (hypospadias in one baby and rotation of 
small intestine in one baby) that were surgically repaired. All babies have continued normal 
growth  and development.  Among female  patients  who interrupted therapy,  five  of  nine  in 
complete hematologic remission (CHR) at the time of treatment interruption eventually lost 
CHR, and six experienced an increase in Philadelphia chromosome–positive metaphases. At 
a median of 18 months after resuming therapy with Imatinib, eight patients had a cytogenetic  
response (complete in three patients).72
Although  there  is  no  evidence  that  a  brief  exposure  to  Imatinib  during  conception  and 
pregnancy adversely affects the developing fetus,  most  patients lose their  response after  
treatment interruption.  Patients receiving Imatinib  should be advised to  practice adequate 
contraception.
Monitoring of CML patients in the era of Imatinib
Cytogenetic analysis has been the mainstay of disease monitoring in CML. Response criteria 
based on the percentage of Ph-positive cells in the bone marrow were established for patients 
on interferon alpha. They have proved to be good predictors of long term response.73 This has 
been used for treatment monitoring in the treatment with Glivec also, which correlated with 
the progression free survival and overall  survival. Although bone marrow cytogenetics can 
also detect clonal evolution and other chromosomal abnormalities and fibrosis apart from t (9;  
22),  it  has  its  limitations  in  the  form of  repeated  invasive  bone  marrow aspirations  and 
possible failure to capture adequate metaphases.
Peripheral blood Fluorescent in situ hybridization (FISH) for t (9; 22) in the interphase cells 
has been evaluated as an alternative to bone marrow cytogenetics. Several studies done 
earlier proved to be of limited sensitivity with false positivity of upto 10% using single fusion  
probes.74 With  the availability of  including either  a second fusion signal  on the derivative 
chromosome 9 or a split of the ABL probe, the sensitivity increased to 1%.75 Steven et al has 
showed  that  interface  FISH agreed  with  conventional  cytogenetics  on  bone  marrow and 
interface FISH on bone marrow and peripheral blood specimens showed strong correlation 
between the two specimens.  There are other studies showing correlation between peripheral  
blood  FISH  and  bone  marrow  cytogenetics.  They  have  however,  cautioned  its  role  at 
diagnosis and monitoring to entirely replace conventional cytogenetics.76 Though not widely 
used, some centers are using peripheral blood FISH to follow up cytogenetic response to 
Imatinib  therapy.  Its  advantage remains at  the early availability (24 hours)  of  results  and 
avoiding a painful procedure to the patient for frequent monitoring. 
Over  the  past  12  years,  several  groups  have  developed  quantitative  RTPCR  assays  to 
measure BCR–ABL transcript levels in the blood and marrow that enabled the dynamics of  
residual disease to be monitored over time and has provided a viable alternative for disease 
monitoring.73,77 The transcript level   correlates with the number of leukemic cells present in 
the  blood  and  marrow  and  can  be  used  as  an  accurate  barometer  of  the  response  to  
therapy.78 The  clinical  usefulness  of  BCR-ABL  quantitation  by  RQ-PCR  has  been 
demonstrated  by  showing  a  strong  correlation  between  the  percentage  of  Ph  positive 
metaphases in the bone marrow and simultaneous study of peripheral blood BCR-ABL levels 
measured by RQ-PCR.79
Status Imatinib for CML in India
Although Imatinib Mesylate (Glivec)  was approved by the FDA for newly diagnosed CML in 
December 2002, cost was a major deterrent for many patients in India. Four months after the 
approval,  from  April  2003,  Max  foundation  through  GIPAP  (Glivec  International  Patient  
Assistance Program) absorbed the cost of the drug and it was made available free of cost to  
the patients of developing countries.  
There has been 2 major studies from AIIMS80 and Tata Memorial hospital, Mumbai68. In the 
former study 118 patients were analyzed (79 in CP, 23 in AP and 16 in BT) and 96% patients  
achieved complete haematological  remission (CHR) and 30% achieved major cytogenetic 
remission. In the advanced phase (AP and BT), the results were 35% and 20% respectively. 
In the second study done from TATA memorial hospital, Mumbai,  174 patients were studied. 
Of them, 97 were in chronic phase, 47 in accelerated phase and 30 patients in blast crisis.  
Among the patients in chronic phase, 50.5% achieved a major cytogenetic response, and 
21.3%, 23.3% in accelerated phase and blast crisis respectively.
                                    AIM OF THE STUDY
To assess the response to Imatinib Mesylate in patients with chronic 
myeloid leukemia in chronic and advanced phase
                             PATIENTS AND METHODS
This was a retrospective and prospective study of 243 patients who came to the department 
of haematology, CMC Vellore starting from January 2002 to December 2005. 
Inclusion criteria:
1. Newly diagnosed Ph positive CML patients.*
2. Interferon unresponsive CML patients.
3. Patients in accelerated or blast phase of chronic myeloid leukemia
*All patients were either peripheral blood or bone marrow FISH (Fluorescent in situ 
hybridization) positive or bone marrow cytogenetics positive for t (9; 22). In the 
absence of the above criteria, patient should be RT PCR positive for BCR/ABL.
Exclusion criteria: Patients with Philadelphia negative myeloproliferative 
disorders. 
Complete history and physical examination were performed on all patients at 
diagnosis and spleen size was documented. If clinical findings and complete blood 
profile are suggestive of CML, then peripheral blood samples were sent for t (9; 22) 
(FISH) for confirmation of diagnosis. In rare situations if FISH was negative RT 
PCR was done. Standard criteria for the diagnoses of chronic phase, accelerated 
phase, and blast crisis were used.81 
Qualification requirements for GIPAP (Glivec International patient Assistance 
Programme)
1. Patient should be properly diagnosed by a physician qualified to diagnose, treat 
and regularly monitor patients with Philadelphia chromosome-positive (Ph+) 
chronic myeloid leukemia (CML) and/or Kit (CD117) positive unresectable 
(inoperable) and/or metastatic malignant gastrointestinal stromal tumours 
(GIST)
2. Patient should meet the inclusion criteria.
3. The patient’s physician must follow treatment guidelines outlined in the Glivec® 
package leaflet and then supply progress information (Patient response every 
90 days)
Financial qualifications:
1. Patient should not be insured.
2. Patient is not reimbursed by any other source.
3. Patient has no other financial resources. (Cannot pay for it privately)
Other qualifications.
1. The patient’s country is a specified qualifying country for GIPAP.
2. The patient’s physician and clinic must be qualified, and be granted approval by The 
Max Foundation to participate in GIPAP.
3. The country must have drug approval for CML and /or GIST.
4. Generic Glivec® (Imatinib) is not available in that country.
Dose of Imatinib:
Patients in chronic phase were initiated at a dose of 400mg once a day and for advanced 
phase at 600mg in two divided doses.  Dose reductions were done as per the 
recommendations82
CRITERIA FOR DIAGNOSIS81
CHRONIC PHASE: (All 5 criteria must be fulfilled) 
1. <15% blasts in PB and BM
2. <30% blasts + promyelocytes in PB and BM
3. <20% basophils in PB
4. >/= 100,000 x 109/L platelets
5. No extramedullary involvement other than spleen or liver.
(In general, patient shouldn’t have any features of accelerated or blast phase)
ACCELERATED PHASE 
MDACC5 IBMTR WHO83
Blasts % in PB 
and/or of 
nucleated bone 
marrow cells
>15% ≥ 10% 10 -19 %
Blasts + 
Promyelocytes
≥ 30% (but < 30% 
blasts alone in 
PB/BM)
≥ 20% NA
Basophils ≥20 % ≥ 20% (Basophils 
+ Eosinophils)
≥ 20%
Platelets x 109 <100 x 10 9/L Unresponsive 
increase or 
persistent 
decrease
<100  x 10 9or 
>1000 x 10 9/L
Cytogenetics CE CE CE
WBC x 109 NA Difficult to control 
or doubling of 
counts <5d
Unresponsive to 
treatment
Anemia NA Unresponsive NA
Splenomegaly NA Increasing Increasing
Others NA Chloromas/
Myelofibrosis
Megakaryocyte 
proliferation, 
fibrosis
MDACC- MD Anderson Cancer Centre (In the Imatinib era this criterion is followed)
IBMTR – International Bone Marrow Transplant Registry
CE – Clonal Evolution
                                          BLAST CRISIS
MDACC criteria84
These two evaluations take preference over chronic and accelerated phase results.
1. ≥ 30% blasts in peripheral blood or bone marrow.
2.  Extramedullary involvement other than spleen or liver
IBMTR criteria
30% blasts plus promyelocytes in the blood or bone marrow 
WHO criteria83
1. Blasts ≥ 20% of peripheral blood white cells or of nucleated bone marrow cells.
2. Extramedullary blast proliferation
3. Large foci or clusters of blasts in the bone marrow biopsy.
PROGNOSIS
 Hasford score85 was calculated in patients with chronic phase using following parameters
1. Age   2. Spleen Size   3. Blasts
4. Basophils    5. Eosinophils    6. Platelets
 The score was calculated using the site  
http:// www.pharmacoepi.de/cmlscore.html   
Low Risk = < 780  (corresponds to median survival 100months)
Intermediate Risk =780-1480 (corresponds to median survival 69 months)
High Risk = >1480  (Corresponds to median survival 45 months)
RESPONSE CRITERIA
HEMATOLOGICAL RESPONSE
COMPLETE HEMATOLOGICAL REMISSION3:
1. Wbc <10,000, Platelets - <4,50,000
2. No immature cells in perepheral blood, myelocytes, promyelocytes, or blasts
(Maintained for 4 weeks)
PARTIAL HEMATOLOGICAL RESPONSE
1. Same as complete  except, persistence of immature cells
2. Platelets <50% of pre-treatment levels, but >4.5 lakhs
3. Persistance of splenomegaly but <50% of pre-treatment size.
Cytogenetic response3
COMPLETE – 0% Ph POS
PARTIAL – 1 – 35%
MAJOR - ≤ 35% (COMPLETE + PARTIAL)
MINOR – 36 – 65 %
MINIMAL – 66 – 95%
NONE - >95%
% of Philadelphia chromosome counted in bone marrow after seeing a minimum of 20 
metaphases.
MOLECULAR RESPONSE9
Complete molecular remission: >/= 4.5log reduction from base line or undetectable levels. 
Major molecular remission: >/= 3 log reduction below the base line or less than 0.045% or 
<0.05%
(the base line can be calculated by the median value of 30 samples collected from 
patients with newly diagnosed chronic phase CML who are untreated or the patient’s 
base line value)
PRIMARY (intrinsic) RESISTANCE86
1.  Failure to achieve complete hematological  remission by 3 months- Primary 
Hematological Resistance (PHR)
2.  Failure to achieve any cytogenetic response by 6 months – Primary cytogenetic 
resistance (PCR).
3.  Failure to achieve MCR by 12 months
      4.   Failure to achieve CCR by 18 months
Acquired resistance (Relapse)
1. Sustained complete hematological remission followed by transformation to AP or BT.
2. Loss of sustained CHR without transformation*.
3.  Loss of MCR** 
4. Loss of CCR with a corresponding increase in BCR-ABL levels of at least 1 log.
*Loss of hematologic remission 
1. WBC >20,000
2. Platelet >6,00,000
      3.  Extra medullary disease
      4.  >5% Myelo + MM
      5.  Appearance of blasts or promyelocytes in PB
            (Done in 2 diff samples 1 month apart)
**Loss of cytogenetic response
Increase in Ph pos cells by 30% in 2 cytogenetic analysis performed 1 month apart. 
Or increase to >65%
Toxicity
Toxicities encountered during therapy were graded as per the National Cancer Institute 
criteria and dose modifications were done as per the toxicity and hematological  and 
cytogenetic responses.87
Monitoring
Patients were monitored by weekly counts for the first month and fortnightly if possible 
thereafter till patient achieved hematological remission and then monthly either in CMC or in 
their home town as per convenience of the patient.  Patients were advised to undergo 
peripheral blood FISH was done a second time (2nd FISH) between 6 months to 1 year and 
every 6 months till they achieved CCR. After achieving CCR, they were monitored by RQ 
PCR.
Peripheral blood fluorescent in situ hybridization (FISH) was performed using LSI BCR/ABL 
Dual color, Dual fusion BCR-ABL translocation probe from Vysis (Vysis Inc. Dowers Grove, 
IL). It is a mixture of the LSI BCR probe labeled with SpectrumGreen™ and the LSI ABL 
probe labeled with SpectrumOrange™.  The spanning ABL probe has a genomic target of 
approximately 650 kb extending from an area centromeric of the argininosuccinate synthetase 
gene (ASS) to well telomeric of the last ABL exon. The BCR probe target spans a genomic 
distance of about 1.5Mb.  The probe begins within the variable segments of the 
immunoglobulin lambda light chain locus (IGLV), extends along chromosome 22 through the 
BCR gene, and ends at a point approximately 900 kb telomeric of BCR.  A region of about 
300 kb containing low-copy number repeats has been eliminated from the probe which 
introduces a gap in the coverage of the probe target.  Both probes span their respective 
breakpoints.
Interpretation of results: A nucleus lacking the t(9;22) translocation will exhibit the two orange, 
two green (2O2G) signal pattern. In a nucleus containing a simple balanced t(9;22), one 
orange, and one green signal from the normal 9 and 22 chromosomes and two orange/green 
(yellow) fusion signals, one each from the derivative 9 and 22 chromosomes, will be observed 
(1O1G2F). In some instances, deletions may occur 3’ of the BCR breakpoint and /or 5’ of the 
ABL breakpoint resulting in either an ES (Extra orange or green) signal pattern or a single 
fusion pattern.  These probes allow a detection of residual disease at the  1 – 2 % level.88  So 
A value of <2% by peripheral blood FISH was taken as complete cytogenetic response and 
the rest of the responses were taken as per the cytogenetic criteria. 
Statistical analysis
Chi square test was used for discrete variables to find out the statistical difference between 
the two groups.  The probability of survival was estimated with the use of the  product limit 
method of Kaplan Meier with death (any cause defined as the event). The probabilities 
between groups were compared with the use of the Log rank statistics. For all tests, a 2 sided 
'p' value of 0.05 or less was considered statistically significant.  SPSS version 11 was used for 
analysis.
                                        RESULTS
Between January 2002 and December 2005, a total of 243 patients who were diagnosed to 
have chronic myeloid leukemia (CML) were retrospectively and prospectively analyzed. All  
these patients were enrolled in the GIPAP (Glivec International Patient Assistance Program) 
at Christian Medical College, Vellore.  Diagnosis of CML was established by peripheral blood 
FISH for bcr/abl translocation or peripheral blood RT PCR for bcr/abl transcripts.
Regional distribution of patients: Figure 1
Patients belonged to 14 different states.  The majority came from Tamil Nadu (40%), West 
Bengal (20%) and the neighboring states of Kerala (15%) and Andhra Pradesh (11%).( Figure 
– 1)
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Base line characteristics (Table -1)
Of the total 243 patients, there were 160 males and 83 females. The M: F ratio was 2:1 and 
the mean age was 38 years. (Range 7 -74 years).  Nine of them were children less than 15 
years of age (Range 7 – 15 years).
Table - 1  Base line characteristics
Characteristic Chronic phase
n (%)
Accelerate
d phase
n (%)
Blast crisis
n (%)
Total
n (%)
Number of 
patients
226 (93) 2 (0.8) 15 (6.2) 243
Sex       
  Male
  Female
151 (67)
75 (33) 2(100)
9 (60)
6 (40)
160 (66)
83 (34)
Age (yrs)
    Median (range) 38 (7 – 74) 46 (42 – 50) 37 (11 – 58) 38 (7 – 74)
WBC at 
diagnosis/cumm
    Median (range)
172500
(50900 – 780000)
3800
(3800 – 
31300)
149325
(9100 – 
592000)
202541 
(3800 – 
780000)
Spleen cm
     Mean (range) 9 (0 – 28) 7 15 (2 – 25) 9 (0-28)
Hasford score at 
diagnosis
Low risk
Intermediate risk
High risk
72 (32)
66(29)
25(11)
NA NA
CML phase prior 
to starting 
Glivec
      
202 (83)
< 1 year 147 (73) 
>1 year 55 (27)
13
(5.3)
28
(11.5)
243
At diagnosis of the disease, 226 (93%) were in chronic phase (CP), 2 (0.8%) in accelerated 
phase (AP) and 15 (6.2%) had progressed to blast transformation (BT). This data is largely 
based on diagnosis made elsewhere at presentation and subsequent referral to this institution 
for treatment with conventional drugs. At the initiation of Glivec, 202 (83%), 13 (5.3%) and 
28(11.5%) were in CP, AP and BT, respectively.  Of the patients in CP, 147 (73%) were 
initiated on Glivec within 1 year of diagnosis (early CP) and 55 (27%) after 1 year of diagnosis 
(late CP).  Hasford score was calculated at diagnosis and 72(32%), 66(29%) and 25 (11%) 
were found to be in low, intermediate and high risk, respectively.
Treatment received prior to starting Glivec in chronic phase
Majority of the patients received Hydroxyurea and Busulfan prior to initiation of Glivec. Twenty 
three patients had received Imatinib of other manufacturers before starting Glivec. The 
median duration of treatment prior to starting Glivec was 2 months ranging from 1 – 180 
months.  (Table – 2)
                                         Table – 2 Treatment prior to Glivec
Drug Frequency(%)
Hydroxyurea 223 (92)
Busulfan 11(4.5)
Interferon 4 (1.6)
Veenat/Zoleta 23 (9.5)
Others 
VCR/Pred – 5
Cytosine - 2
7 (2.8)
Median duration of treatment given prior to starting Glivec- 2 months (1 – 180)
Overall response to Imatinib 
Although 202 patients in CP, 13 patients in AP and 28 patients in BT were enrolled at the time 
of diagnosis, only 182 patients in the chronic phase  (136 in <1 yr group, 46 in >1 yr group) 
were evaluable at 3 months to assess haematological response as others were lost to follow 
up before 3 months. (Table – 3)
Table - 3
Phase of 
CML
Chronic phase Acclerated 
phase
Blast crisis
Early and 
late 
chronic 
phase 
combined
CP <1yr 
(Early phase) 
from 
diagnosis
N/total
CP >1 yr
 (late phase) 
from diagnosis
N/total/
CHR at 3 
months
(%)
165/182
(91)
125/136
(92)
40/46
(87)
9/13
(69)
15/28
(54)
MCR
(%)
Median time 
range
82/117
(70)
69/89 (Partial 
CR 19)
 (77.5)
8 months
(3 – 34)
13/28 (Partial CR- 
3)
 (46.4)
10 months
(3 – 18)
2/6 (Partial CR- 
0)
(33.3)
19 months
19
2/7(Partial CR- 
1)
(28.5)
8.5 months
6-11
CCR
(%)
Median time 
range
60/117
(51.2)
50/89 
(56)
10 months
 (4 – 40)
10/28 
(35.7)
13 months 
(6 – 30)
2/6
(33.3)
19 months
19
1/7
(14.2)
6 months
6
MMR
(%)
Median time
range
4/30
(13)
3/22
(13.6 of 
evaluable CCR 
pts)
24 months
15 - 40
1/8
(12.5)
20 months
- -
CMR 1/22 1/22 - - -
      CP – 202 pts
CP – 182 pts evaluable CP – 20 patientsNot evaluable 
At 3 
months
(%)
Median time
range
(4.5) (4.5)
18
18
At 3 months, complete haematological response (CHR) were noted in 91% of the patients in 
chronic phase,  69% of patients in accelerated phase and 54% of patients in blast crisis.  Of 
the patients in chronic phase, 92% CHR was observed in early chronic phase and 87% in late 
chronic phase. Seventy percent patients in chronic phase achieved major cytogenetic 
response, (77.5% in early CP and 46.4% in late CP) 33.3% in accelerated phase and 28.5% 
in blast transformation. Complete cytogenetic response was achieved in 51.2% of chronic 
phase patients (56% in early CP and 35.7% in late CP) but only 33.3% and 14.2% among 
accelerated phase and blast transformation respectively.  The difference between the early 
and late chronic phase response for MCR alone was statistically significant. (PHR p value = 
0.16, MCR- p Value = 0.001 , CCR - p value = 0.12)
Molecular response was evaluated in 30 patients who achieved CCR in the chronic phase 
and 13% were noted to have major molecular response (MMR). Only one patient achieved 
complete molecular response (CMR).
Resistance to Imatinib89
Primary Haematological resistance (PHR) was noted in 9% of patients in chronic phase (8% 
in early chronic phase and 13% in late chronic phase: p value – 0.23).   It was 23% and 50%  
in patients with AP and BT respectively.  Primary cytogenetic resistance was noted in 12.5% 
of early chronic phase patients and 46% of late chronic phase patients. This difference was 
statistically  significant.  (p  value  <0.001).  In  the  AP and  BT groups,  primary  cytogenetic  
resistance was noted in 50% and 57% patients respectively (Cytogenetic response status 
could be evaluated only in 6 patients in AP and 7 patients in BT) (Table – 4)
Table – 4  Resistance to Imatinib
Chronic phase AP BT
Overall CP CP <1 yr CP >1 yr
PHR 17/182
(9.3)
11/136
(8)
6/46
(13)
3/13
(23)
14/28
(50)
PCR 21/98
(21.4)
9/72
(12.5)
12/26
(46)
3/6
(50)
4/7
(57)
PHR- Primary haematological resistance, PCR- Primary cytogenetic resistance
Evaluation of cytogenetic responses in patients  of  chronic phase. 
A total of 57% of patients underwent peripheral blood FISH ((t (9; 22)) examination as part of 
cytogenetic evaluation. 72% of the patients underwent 2nd peripheral blood FISH ((t (9; 22)) 
examination between 3 and 12 months. (Table – 5)
Table – 5 Cytogenetic evaluation at various time intervals
Months in 
category
MCR Min CR CCR PCR
<1 yr >1yr <1 yr >1 yr <1 yr >1yr <1 yr >1 yr
3 – 12
(%) 
54/75 
(72)
9/20
(45)
19/75
 (25.3)
7/20
(35)
37/75
(49)
3/20 
(15)
2/75 
(2.6)
4/20
(20)
13 – 18 
(%)
6/8
 (75)
8/15
 (53)
Nil Nil 5/8
(52.5
)
3/7
(43)
2/8 
(25)
4/7
(57)
19 – 24 3/4 4/7 Nil 2/3 3/4 Nil ¼ (25) 1/3
(%) (75) (57) (66.7) (75) (33.3)
>24
(%) 
2/3
(66.7)
3/6
(50)
Nil 1/3
(33)
Nil 1/3
(33.3)
1/3 
(33.3)
Nil 
MCR – Major cytogenetic response, Min CR- Minimal cytogenetic response, CCR- complete 
cytogenetic response, PCR- Primary cytogenetic resistance.
Cytogenetic response status at specific time intervals in patients started on Glivec in Chronic 
phase 
At 6 months Partial cytogenetic response was observed in 24% patients and it was 20.5%, 
19.2%, 18% and 19% at 1 year, 1 ½ years, 2 years and >2 years respectively. Complete 
cytogenetic response was observed in 50%, 50.6%, 53%, 53% and 51.2% at 6 months, 1 
year, 1 ½ years, 2 years and >2 years respectively. Major cytogenetic response was observed 
in 73%, 71%, 72.2%, 71% and 70% at the same intervals.  Minor and minimal cytogenetic 
responses were 26%, 29%, 28%, 29% and 30% also at the same intervals. Differences 
between any of these responses were not statistically significant. Molecular responses were 
evaluated in 30 chronic phase patients who achieved CCR and major molecular response 
was observed in 13% of patients and complete molecular response in 4.5% of patients.
Table – 6 Cytogenetic response status at specific time intervals in CP patients
6months
N / evaluable 
pts
(%)
1 yr
N / 
evaluable 
pts
(%)
1 ½ yr
N / 
evaluable 
pts
 (%)
2 yrs
N / 
evaluable 
pts
 (%)
>2 
yrswe 
N / 
evaluable 
pts
P value
Partial cytogenetic 
response 
10/42
(24)
17/83
(20.5)
20/104
(19.2)
20/111
(18)
22/117
(19)
0.94
Complete cytogenetic 
response
21/42
(50)
42/83 
(50.6)
55/104 
(53)
59/111
(53)
60/117
(51.2)
0.99
Major cytogenetic 
response 
(Partial CR + CCR)
31/42 
(73)
59/83 
(71)
75/104 
(72.2)
79/111 
(71)
82/117
(70)
0.99
Minor and Minimal 
Cytogenetic
Response     (Min CR)
11/42
(26)
24/83 
(29)
29/104
(28)
32/111
(29)
35/117
(30)
0.99
Major Molecular 
Response
- - - 3/22
(13)
CompleteMolecular 
Response
- - - 1/22
(4.5)
Figure – 2 Overall survival from after starting Glivec in chronic phase (CP), 
accelerated phase (AP) and blast transformation (BT)
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At a mean follow up of 46 months (1 – 47 months), the overall survival in chronic phase was 
98 ± 0.01%.  For accelerated phase, the OS was 54 ± 0.20% at a mean follow up of 28 
months (1 – 40 months)  and for blast crisis it was 51 ± 0.13% at a mean follow up of 24 
months (1 – 42 months).(Figure 2)
Progression free survival (PFS) after starting Glivec in various phases
Figure – 3
The PFS in CP, AP and BT were 81 ± 0.07%, 64 ± 0.10%, and 48 ± 0.19% at mean follow up 
periods of 42 months (1 – 47months) , 28 months(1 – 40 months) and 26 months (0 – 42 
months) respectively. (Figure 3)
AP -54 ± 0.20%
Mean FU – 28 months 
CP– 98 ± 0.01%
Mean FU– 46 months 
Figure 2 P value < 0.001
BT -51 ± 0.13%
Mean FU – 24 months
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Progression free survival in chronic phase CML – Figure 4
The progression free survival in chronic phase patients in CML was 85 ± 0.05% in early CP at 
42 months (1 – 47 months) and 81 ± .011% in late CP at 39 months (1 – 43 months). In log 
rank analysis, there was no apparent difference between the two groups.
Figure - 3P value - <0.001
Accelerated phase – 48 ± 0.19 %
Mean FU– 28 months 
Chronic phase – 81 ± 0.07%
Mean FU – 42 months 
Blast crisis – 64 ± 0.10%
Mean FU– 26 months
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Progression free survival in Chronic phase (early and late CP),according to 
Cytogenetic response. Figure - 5
PFS in early and late chronic phase patients in CCR were 100% (1 – 31 months).  For 
patients in Minor/minimal CR, at a mean follow of 37 months (4 – 43 months) the PFS was 84 
+ 0.07% and for patients in partial CR, the PFS was 78 ± 0.13% at a mean follow up of 41 
months (3 – 47 months). (Figure – 4)
Figure - 4P value – 0.41
Late CP-  81± 0.11 %
 Mean FU-39  months 
<Early CP -  85 ± 0.05%
 Mean FU-42  months 
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Overall survival on patients with Glivec in relation to Hasford score – Figure - 
6
The Hasford score risk stratification did not show any correlation with the survival curves. 
(Figure – 6)
Figure - 5P value – 0.03
Partial CR 78 ± 0.13%  
Mean FU 41 months
Minor/Minimal CR – 84 ± 0.07%
– Mean FU – 37 months
CCR–  PFS 100% 
High risk – No event 100%
1 – 47months
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Haematological toxicity on Glivec
Haematological toxicity was noted in 14% of patient in chronic phase, 23% in Accelerated 
phase and 50% of patients in blast transformation. (Table – 7)
Table - 7
Toxicity CP 
any grade 
n/total
(%)
CP 
grade 3 
or 4
n/total
(%)
AP any 
grade
n/total
(%)
AP 
grade
3 or 4
n/total
(%)
BT 
any 
grade
n/total
(%)
BT 
grade 3 
or 4
n/total
(%)
Haematological toxicity 
present
28/202 
(14)
3/13 
(23)
14/28 
(50)
Neutropenia 21/202 
(9)
9/202 2/13 
(15)
nil 14/28
(50)
11/28
Mean time from start of 
treatment(weeks)
8
2 -28
- 1.5
1-2
- 2
1 - 8
-
Thrombocytopenia 22/202 
(11)
11/202 2/13 
(17)
1/13 9/28 
(33.3)
9/28
Figure - 6
Intermediate risk  94 ± 0.03% 
Mean FU - 33 months  
(2 – 35 months)
Low risk –– 96 ± 0.02%
Mean FU - 29 months 
(1 – 30 months)
P value - 0.431
Mean time from start of 
treatment (weeks)
8.5
1 - 36
- 2
2
- 2
1-4
-
Anaemia 8/202 
(4)
6/202 1/13 (8) 1/13 7/28 (25) 5/28
Mean time from start of 
treatment (weeks)
3
2 - 28
- 2
2
- 2
1-6
-
Bone marrow aplasia 4/202 
(2)
- NA - NA -
Time of onset to BM 
aplasia (weeks)
12
10 - 28
- - - - -
Non hematological toxicities observed in various phases of CML
The overall non- haematological toxicity were noted in 17% of patients in chronic phase and 
30% of patients in accelerated phase and blast transformation. (Table – 8)
Table - 8
                                             DISCUSSION
Introduction  of  Imatinib  has  made  a  paradigm  shift  in  the  treatment  of  chronic  myeloid 
leukemia in the true sense of “magic bullet” in cancer chemotherapy. As BCR-ABL remains 
unique to induce leukemogenesis, Imatinib serves as the ideal treatment in CML.  
A total of 243 patients from 14 different states in India were analyzed who had enrolled in 
GIPAP at our centre.  Majority (40%) of patients belonged to Tamil Nadu, and West Bengal  
was  second  highest  (20%)  similar  to  the  hospital  statistics.  This  was  followed  by  the  2 
neighboring states, Kerala (15.2%) and Andhra Pradesh (11.1%). (Figure – 1)
Chronic myeloid leukemia is noted to be higher among the males and the ratio is usually 1.4:1 
in Western countries.90  However, Indian studies have shown higher male preponderance with 
ratios of 2.3:168 and 3.4:180 similar to our study (2:1).
The median age of onset of disease in the Western population ranges from 45 to 55 years. It 
is noted to be much earlier in the Indian population with 38 (4-79)68 and 38 (11 – 65)80 very 
much similar  to  the present  study (38 (7 – 74)).  About  12 to  30 percent  of  the Western 
population are more than 60 years of age91. In our study, only 5% belonged to that group and 
78% of  patients  were  less  than  50  years  of  age,  55% less  than  40  years  and  44% of 
population were between 20 to 40 years of age. Only 9 patients belonged to the pediatric  
population. (<15 years) (Table – 1)
Hasford score was calculated for 163 out of 226 patients in chronic phase and 32%, 29% and 
11% were noted to be in low, intermediate and high risk groups. (Figure -6)
Patients in chronic phase on Glivec were subdivided into initiation of treatment before 1 year  
(early chronic phase) (147 (65.5%)) and more than 1 year from diagnosis (late chronic phase) 
(55 (34.5%)). (Table – 1)
Majority of the patients were pretreated with Hydroxyurea (92%) followed by Veenat/Zoleta 
(23%) and Busulfan (4.5%) prior to the initiation of therapy for a median of 2 months (1 –  
180).   This  time duration was either  because patients were  initiated  on treatment  before 
coming to CMC or during the waiting period of getting the GIPAP approval.
The overall response in chronic phase were categorized into early (<1 yr from diagnosis) and 
late chronic phase (>1 year from diagnosis). The results were comparable for CHR, MCR and 
CCR in terms of the other western and Indian studies. (Table-9). The MCR was significantly 
higher  in  early  versus  late  chronic  phase  patients  in  our  study  similar  to  the  study  by 
Kantarjian et al in interferon failure group.
However AP and BT responses were marginally lower.  The differences between were not 
statistically significant (p – 0.65). 
Table - 9
Study Number of 
patients
CHR % MCR % CCR %
Chronic phase
S O’Brien et al8
(IRIS) – Newly 
diagnose- at 
400mg. Median 
follow up of 19 
months
553 95.3 87.1 76.2
Kantarjian et al92
(Interferon failure)
261 95 62 45
Kantarjian et al93
Newly diagnosed 
at 800mg
114 96 96 90
Deshmukh et al68 
Early chronic phase
Late chronic phase
24
73
100
89
62.5
46.4
41.7
27.3
Arora et al80
Median follow up 
of 5 months
79 95.8 30 16
Present study
Early chronic phase)
Late chronic phase)
147
55
92
87
77.5
46.4
56
35.7
Accelerated phase
Kantarjian et al94 200 80 45 24
Talpaz et al6 235 82 24 17
Deshmukh et al68 47 55.3 21.3 6.4
Arora et al80 23 45 20
Present study 13 54 33.3 33.3
Blast crisis
Kantarjian et al84 75 21.3 10.6 6.6
Sawyer et al7 260 52 16 7
Deshmukh et al68 30 36.7 23.3 13.3
Arora et al80 16 20 20
Present study 28 75 28.5 14.2
The molecular responses noted in our study at a median follow up of 24 months were much 
lower than the earlier studies. The probable reason was that only 30 patients who achieved 
CCR got RQ PCR analysis. The criteria used here was BCR-ABL/ABL ratio of <0.0595 to  call 
it Major molecular remission. However, as per the proposed guidelines of keeping the cutoff 
for MMR at 0.1%96, the percentage of MMR increases to 31.8% (7/22). (Tables 3 & 11)
Table – 10          Molecular response in chronic phase
Study Number of 
patients
MMR (BCR-
ABL/ABL)
0.05%
CMR
Hughes et al9
Newly diagnosed at 
400mg
(Median follow up 12 
months)
553 39 3
Kantarjian et al.93 
Newly diagnosed at 
800mg
(Median follow up
15 months)
114 63 28
Kantarjian et al95
Post interferon failue
(Median follow up 45 
months)
261 43 26
Present study
Median follow up 24 
months
30 evaluable 
patients of the 53 
who achieved 
CCR
13 4.5
The incidence of haematological resistance in the earlier studies97 is shown in table 11.  The 
incidence of resistance in early and late chronic phase is similar to the previous studies. 
There is significant difference in the AP and BT groups, probably due to smaller numbers 
analyzed.
Table - 11
Phase of CML Haematological 
resistance
Cytogenetic resistance
Newly diagnosed CML- 
CP.  Hughes et al8
PHR – 5% at median FU 
18 months
4% relapse or progression
14% at 18 months, 12 % 
after 24 months and
10% relapse or progression
Interferon treated CML – 
CP
PHR – 5% median FU of 
18 months
13% relapse or 
progression
40% after 18months
36% at 24 months
Accelarated phase 24% PHR and 51% 
relapse after 2 years.
76 % at 12 months
Blast crisis 66% PHR and 88% 
relapse at 2 years.
84% at 12 months
Present study
at a median follow up of 46 
months in CP, 28 months in AP 
and 24 months in BT
PHR CP <1 year – 8%
         CP >1 year – 9%
            AP – 25%
            BT – 15%
CP <1 year 12.5%
CP >1 year 46%
AP 50%
BT 57%
The cytogenetic responses at various time periods were analyzed separately because there 
was no uniformity in the timing of 2nd FISH (t (9; 22) due to logistic reasons. Many of our 
patients are coming from far (West Bengal – 20%) and only 40% of patients belonged to Tamil  
Nadu.  Majority (69%) of the patients got the 2nd Fish done before 1 year (3 – 12 months). 
Table – 5.  Third FISH (t (9; 22) test could only be done in 22 patients. 
Response status (Table – 7) at various time intervals in chronic phase shows similar trend 
from 6 months onwards. However, partial cytogenetic responses show a marginal decrement 
and increase in complete cytogenetic response. The Major cytogenetic response remained 
almost the same. This could possibly because we have analyzed both the early and late 
chronic  phases  together  and  response  evaluation  was  done  at  different  time  points  for 
different patients. The follow up of IRIS8 study patients shown below.
Table - 12
CHR MCR CCR PFS
Months 
follow up
24 42 24 42 24 42 24 42
Estimated 
rate (%)
Not 
reported
98 88 91 79 84 96 94
The overall survival after starting Glivec in CP, AP and BT were 98%, 54% and 51% at mean 
follow  up  of  46  months,  28  months  and  24  months  respectively.  Two  patients  in  Blast 
transformation received Vincristine and prednisolone along with  Glivec for  lymphoid  blast  
transformation. The OS in patients in chronic phase is similar to the other studies.8,95 (Figure – 
2)
The progression free survival (PFS) in CP, AP and BT were 81%, 64% and 48% at mean 
follow up of 42 months, 28 months and 26 months respectively. The PFS in the chronic phase 
is lower as compared to the IRIS study because here we have combined both early and late 
chronic phase (Figure – 3).  When the chronic phase patients were analyzed separately, early 
phase CP showed PFS of 85% at a mean follow up of 39 months (Figure – 4).  The PFS in  
the late phase CML is comparable to the study by Kantarjian et al. 8,95 
IRIS study – PFS – 93% at 24 months8    Interferon failure – OS 88% and PFS 83%95
Patients in chronic phase (both early and late chronic phase) were further analyzed for PFS 
according to the cytogenetic response (Figure 5).  The PFS was 100% in the CCR group 
indicating that no matter whether the patient is in early or late chronic phase, if CCR can be 
achieved, PFS improves dramatically. It was 78% in the partial CR group (41months) and 
84% in minor/minimal CR group (37 months).  This is comparable with the IRIS study which 
showed that achieving CCR by 12 months shows marked reduction in progression (PFS – 
100%).
The overall survival was compared with Hasford score which was proved to be an important 
tool in predicting survival for patients on interferon.85,98 But it has not shown any correlation 
treatment with Imatinib. This was consistent in our study also. (Figure – 6)
Haematological toxicity profile was similar to the other studies with 14% in the chronic phase, 
23% in the accelerated phase and 50% in blast transformation. (Table–7). Five patients in 
chronic phase (2%) developed bone marrow aplasia during the course of treatment with a 
median time onset of 12 weeks. (10 – 28 weeks). There are only case reports of patients  
developing bone marrow aplasia99 and pretreatment with interferon and Busulfan has been 
considered to be a risk factor. Among the 5 patients who developed BM aplasia, 4 of them 
were initiated on Glivec in late chronic phase (40, 36, 37 and 13 months from diagnosis.) and 
only  1  patient  was  started  on  Glivec  in  early  chronic  phase.  Assessment  of  non  – 
haematological toxicity profile was not well co-ordinated and the same cannot be commented 
upon. (Table- 8).
SUMMARY AND CONCLUSIONS
This study was performed on 243 patients with chronic myeloid leukemia who came to CMC 
Vellore and was eligible to enroll  into GIPAP for Imatinib Mesylate (Glivec).  Response to 
treatment was monitored by regular blood counts and peripheral blood FISH for t (9; 22).
1. Male: Female ratio was 2:1.
2. Mean age of diagnosis was 38 years (7 – 74).
3. A total of 202 (83%) of patients were in chronic phase, 12 (5.3%) in accelerated phase 
and 28 (11.5%) patients were in blast crisis at the time of starting Imatinib (Glivec). Of 
the 202 patients in chronic phase, 147 (65.5%) of patients were started on Imatinib < 1 
year from (Early chronic phase) from diagnosis and 55 (27%) of patients were >1 year 
form (late chronic phase) diagnosis.
4. Majority of patients were on Hydroxyurea (92%) and Busulfan (4.5%) prior to initiation 
of Imatinib (Glivec). The median duration of treatment prior to initiating Imatinib was 2 
months.
5. Complete  haematological  response  (CHR)  at  3  months  was  observed  in  92%  of 
patients in early chronic phase and 87% in late chronic phase (overall 91%).  It was 
69% and 54% in accelerated phase and blast crisis respectively.
6. Major cytogenetic remission (MCR) was observed in 77.5% of patients in early chronic 
phase and 46.4 % in late chronic phase (overall 70%).  The difference was statistically 
significant (p <0.001). MCR was seen in 33.3% of accelerated phase and 28.5% of  
blast crisis patients. 
7. Complete  cytogenetic  remission  (CCR)  was  observed  in  56% of  patients  in  early 
chronic phase and 35.7% in late chronic phase (overall 51.2%). The difference was 
statistically not significant.  CCR was seen in 33.3% of accelerated phase and 14.2% 
of blast crisis patients.
8. Major molecular remission was observed in 13.6% of early chronic patients in CCR 
and 12.5% in late chronic phase (overall 13%). Complete molecular remission (CMR) 
was observed in only one patient (4.5%) in early chronic phase.
9. Primary haematological resistance (PHR) was noted in 8% of early chronic phase and 
13 % in late chronic phase (overall 9.3%). The same was 25% and 50% in accelerated 
phase and blast crisis respectively.
10. Primary cytogenetic resistance (PCR) was observed in 12.5% of early chronic phase 
CML  and  46%  of  late  chronic  phase  CML  (overall  21.34%).  The  difference  is 
statistically significant. (p <0.001).  PCR was 50% in the accelerated phase and 57% in  
the blast crisis.
11. A total of 57% of patients underwent peripheral blood FISH examination. 72% of them 
underwent 2nd FISH examination between 3 and 12 months.  There was no difference 
in the cytogenetic response rates in chronic phase CML at various time intervals.
12.The overall survival (OS) in chronic phase was 98% at a mean follow up of 46 months. 
The OS in accelerated phase was 54% at a mean follow up of 28 months and in blast 
crisis it was 51% at 24 months.
13. The progression free survival (PFS) in chronic phase was 81%, in accelerated phase it  
was 48% and for blast crises it was 64%. The Mean follow ups were 42 months, 28 
months and 26, months respectively.
14.   The progression free survival in chronic phase patients in CML was 85% in early CP 
at 42 months and 81% in late CP at 39 months. The difference was not statistically 
significant.
15. PFS  in  early  and  late  chronic  phase  patients  in  CCR  were  100%,  84%  with 
Minimal/Minor CR, and 78% with Partial CR. 
16.There  was  no  correlation  with  Hasford  score  at  diagnosis  and  overall  survival  in 
patients on Glivec.
17.Haematological  toxicity  was  noted  in  14%  of  patients  in  chronic  phase,  23%  in 
accelerated phase and 50% of patients in blast transformation.
18. The overall  non-  haematological  toxicity  were  noted  in  17% of  patients  in  chronic 
phase and 30% of patients in accelerated phase and blast transformation.
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Objective: To assess the response to imatinib mesylate in patients with chronic myeloid 
leukemia in chronic and advanced phase who came to our institution from January 2002 to 
December 2005.
Methods: All  Chronic  Myeloid  Leukemia  patients  who  were  eligible  to  enroll  into  GIPAP 
(Glivec  International  Patient  Assistance  Program)  for  imatinib  were  included  for  analysis.  
Response to treatment was analyzed by peripheral blood counts and peripheral blood FISH 
analysis for t(9;22) at various intervals.  This was subsequently correlated with overall survival  
and progression free survival using log-rank test.
Results: A total of 243 patients were enrolled into the study (CP-202, AP – 13, BT – 28). 
Complete haematological remission was achieved in 91% of patients in CP, 69% in AP and 
57% in BT.  Major cytogenetic remission was observed in 70% of patients in CP, 33.3% in AP 
and 28.5% in BT.  Complete cytogenetic remission was observed in 51.2% of patients in CP, 
33.3% in AP and 14.2% in BT. The overall survival in CP was 98%, and for AP and BT, it was  
54% and 51%.  The Progression Free Survival in CP was 81% and for accelerated and blast  
crisis, it was 48% and 64%. 
Conclusion: There  is  significant  hematological  and  cytogenetic  response  to  Imatinib 
Mesylate in patients with chronic myeloid leukemia.
 

